Abstract
Glioblastoma is the most common, aggressive and lethal brain tumor in adults. However, current therapeutic protocols have low success rates and average overall survival is less than 15 months. The resistance to therapy is largely a result of the remarkable cellular and phenotypical heterogeneity that characterizes this type of tumor. The discovery of a subpopulation of cells exhibiting stem cell properties within the tumor bulk has profound implications for therapy as increasing evidence indicates that these cells, glioblastoma stem cells (GSCs), are responsible for the origin, maintenance and recurrence of the glioblastomas. These findings highlight the need to characterize GSCs in order to find novel treatments directly targeted specifically against them. In this review, we summarize the current knowledge regarding this issue, including some recent and relevant patents.
Keywords: Glioblastoma, glioblastoma stem cells, molecular target, therapy.
Recent Patents on Anti-Cancer Drug Discovery
Title:Therapeutic Strategies Targeting Glioblastoma Stem Cells
Volume: 8 Issue: 3
Author(s): Estefania Carrasco-Garcia, Nicolas Sampron, Paula Aldaz, Olatz Arrizabalaga, Jorge Villanua, Cristina Barrena, Irune Ruiz, Mariano Arrazola, Charles Lawrie and Ander Matheu
Affiliation:
Keywords: Glioblastoma, glioblastoma stem cells, molecular target, therapy.
Abstract: Glioblastoma is the most common, aggressive and lethal brain tumor in adults. However, current therapeutic protocols have low success rates and average overall survival is less than 15 months. The resistance to therapy is largely a result of the remarkable cellular and phenotypical heterogeneity that characterizes this type of tumor. The discovery of a subpopulation of cells exhibiting stem cell properties within the tumor bulk has profound implications for therapy as increasing evidence indicates that these cells, glioblastoma stem cells (GSCs), are responsible for the origin, maintenance and recurrence of the glioblastomas. These findings highlight the need to characterize GSCs in order to find novel treatments directly targeted specifically against them. In this review, we summarize the current knowledge regarding this issue, including some recent and relevant patents.
Export Options
About this article
Cite this article as:
Carrasco-Garcia Estefania, Sampron Nicolas, Aldaz Paula, Arrizabalaga Olatz, Villanua Jorge, Barrena Cristina, Ruiz Irune, Arrazola Mariano, Lawrie Charles and Matheu Ander, Therapeutic Strategies Targeting Glioblastoma Stem Cells, Recent Patents on Anti-Cancer Drug Discovery 2013; 8 (3) . https://dx.doi.org/10.2174/15748928113089990002
DOI https://dx.doi.org/10.2174/15748928113089990002 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Using Feature Selection Technique for Drug-Target Interaction Networks Prediction
Current Medicinal Chemistry The Use of Propolis in Micro/Nanostructured Pharmaceutical Formulations
Recent Patents on Drug Delivery & Formulation Two-Domain Vascular Disruptive Agents in Cancer Therapy
Current Cancer Drug Targets NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Current Cancer Therapy Reviews The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy
Current Drug Targets Fireflies in the Coalmine: Luciferase Technologies in Next-Generation Toxicity Testing
Combinatorial Chemistry & High Throughput Screening The Breakthroughs in Cancer Immune Checkpoint Based Therapy: A Review of Development in Immune Checkpoint Study and its Application
Combinatorial Chemistry & High Throughput Screening Synthesis and Cytotoxic Properties of Halogen and Aryl-/Heteroarylpiperazinyl Derivatives of Benzofurans
Anti-Cancer Agents in Medicinal Chemistry CDC25 Inhibitors as Anticancer Agents Are Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Current Drug Targets Role of Angiopoietin-like 4 (ANGPTL4), a Member of Matricellular Proteins: from Homeostasis to Inflammation and Cancer Metastasis
Current Angiogenesis (Discontinued) In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies
Current Medicinal Chemistry The Relevance of Microdialysis for Clinical Oncology
Current Clinical Pharmacology ABC Subfamily D Proteins and Very Long Chain Fatty Acid Metabolism as Novel Targets in Adrenoleukodystrophy
Current Drug Targets Cisplatin Analogues with an Increased Interaction with DNA: Prospects for Therapy
Current Pharmaceutical Design Novel Diaryl or Heterocyclic Sulfonamides as Antimitotic Agents
Anti-Cancer Agents in Medicinal Chemistry Atrial Remodeling and Novel Pharmacological Strategies for Antiarrhythmic Therapy in Atrial Fibrillation
Current Medicinal Chemistry Targeted Liposomes for siRNA Delivery to Cancer
Current Pharmaceutical Design Antiproliferative Activity of microRNA-125a and its Molecular Targets
MicroRNA Synthesis, Antiproliferative, and Antiangiogenic Activities of Benzochromene and Benzoquinoline Derivatives on Prostate Cancer in vitro
Letters in Drug Design & Discovery